ANZMTG - Australia and New Zealand Melanoma Trials Group Home | Login
ANZMTG - Australia and New Zealand Melanoma Trials Group
 

LOGIN



Please enter your username and password.


Username

Password


  
ANZMTG
 

ANZMTG - MSLT II

A phase III multicenter randomised trial of sentinel lymphadenectomy and complete lymph node dissection versus sentinel lyphadenectomy alone, in cutaneous melanoma patients with molecular or histopathological evidence of metastases in the sentinel node (MSLT II).

Study status - Open to recruitment

Chief Investigator:

USA:
Dr Don Morton John Wayne Cancer Institute, CA, USA
(800) 262 6259

Australia
Prof John Thomspon
Melanoma Insitute Australia
61 2 9911 7366

ANZMTG coordinator details:

Email: anzmtg@melanoma.org.au
Phone: +61 2 9911 7348

 

Documents (PDF downloads – currently in development):


Return to Previous Page